A top cardiologist is accusing a drug maker with whom he worked closely of making misleading statements about its weight loss medicine and refusing to release data that would undermine its previous claims.
The pill, Contrave, was prescribed 117,000 times in its first three months on the market, a better launch than any obesity drug in the past decade. Things seemed to get even better in March, when Contrave’s maker, Orexigen Therapeutics OREX -13.41%, released data that claimed that the drug not only helped patients lose weight but also prevented heart attacks, strokes and deaths caused by cardiovascular disease by a stunning 41%, a statistically significant amount.
Hey, check out all the research scientist jobs. Post your resume today!
